Dynamic Contrast-enhanced MRI Perfusion for Differentiating Between Melanoma and Lung Cancer Brain Metastases

Overview

Journal Cancer Med

Specialty Oncology

Date 2017 Mar 18

PMID 28303695

Citations 15

Authors

Vaios Hatzoglou

Jamie Tisnado

Alpesh Mehta

Kyung K Peck

Mariza Daras

Antonio M Omuro

Kathryn Beal

Andrei I Holodny

Affiliations

Soon will be listed here.

Abstract

Brain metastases originating from different primary sites overlap in appearance and are difficult to differentiate with conventional MRI. Dynamic contrast-enhanced (DCE)-MRI can assess tumor microvasculature and has demonstrated utility in characterizing primary brain tumors. Our aim was to evaluate the performance of plasma volume (Vp) and volume transfer coefficient (K ) derived from DCE-MRI in distinguishing between melanoma and nonsmall cell lung cancer (NSCLC) brain metastases. Forty-seven NSCLC and 23 melanoma brain metastases were retrospectively assessed with DCE-MRI. Regions of interest were manually drawn around the metastases to calculate Vp and Kmeantrans. The Mann-Whitney U test and receiver operating characteristic analysis (ROC) were performed to compare perfusion parameters between the two groups. The Vp of melanoma brain metastases (4.35, standard deviation [SD] = 1.31) was significantly higher (P = 0.03) than Vp of NSCLC brain metastases (2.27, SD = 0.96). The Kmeantrans values were higher in melanoma brain metastases, but the difference between the two groups was not significant (P = 0.12). Based on ROC analysis, a cut-off value of 3.02 for Vp (area under curve = 0.659 with SD = 0.074) distinguished between melanoma brain metastases and NSCLC brain metastases (P < 0.01) with 72% specificity. Our data show the DCE-MRI parameter Vp can differentiate between melanoma and NSCLC brain metastases. The ability to noninvasively predict tumor histology of brain metastases in patients with multiple malignancies can have important clinical implications.

Citing Articles

Radiosurgery for Brain Metastases: Challenges in Imaging Interpretation after Treatment.

Romano A, Moltoni G, Blandino A, Palizzi S, Romano A, de Rosa G Cancers (Basel). 2023; 15(20).

PMID: 37894459 PMC: 10605307. DOI: 10.3390/cancers15205092.

A Review on the Use of Imaging Biomarkers in Oncology Clinical Trials: Quality Assurance Strategies for Technical Validation.

Chauvie S, Mazzoni L, ODoherty J Tomography. 2023; 9(5):1876-1902.

PMID: 37888741 PMC: 10610870. DOI: 10.3390/tomography9050149.

From Pixels to Pathology: Employing Computer Vision to Decode Chest Diseases in Medical Images.

Arslan M, Haider A, Khurshid M, Abu Bakar S, Jani R, Masood F Cureus. 2023; 15(9):e45587.

PMID: 37868395 PMC: 10587792. DOI: 10.7759/cureus.45587.

An Effective Approach to Improve the Automatic Segmentation and Classification Accuracy of Brain Metastasis by Combining Multi-phase Delay Enhanced MR Images.

Chen M, Guo Y, Wang P, Chen Q, Bai L, Wang S J Digit Imaging. 2023; 36(4):1782-1793.

PMID: 37259008 PMC: 10406988. DOI: 10.1007/s10278-023-00856-3.

Advanced MRI to differentiate schwannomas and metastases in the cerebellopontine angle/internal auditory canal.

Ota Y, Liao E, Zhao R, Lobo R, Capizzano A, Bapuraj J J Neuroimaging. 2022; 32(6):1177-1184.

PMID: 35879866 PMC: 9796724. DOI: 10.1111/jon.13028.

References

Saha A, Peck K, Lis E, Holodny A, Yamada Y, Karimi S . Magnetic resonance perfusion characteristics of hypervascular renal and hypovascular prostate spinal metastases: clinical utilities and implications. Spine (Phila Pa 1976). 2014; 39(24):E1433-40. PMC: 4465934. DOI: 10.1097/BRS.0000000000000570. View

Arevalo-Perez J, Kebede A, Peck K, Diamond E, Holodny A, Rosenblum M . Dynamic Contrast-Enhanced MRI in Low-Grade Versus Anaplastic Oligodendrogliomas. J Neuroimaging. 2015; 26(3):366-71. PMC: 5510484. DOI: 10.1111/jon.12320. View

Grommes C, Oxnard G, Kris M, Miller V, Pao W, Holodny A . "Pulsatile" high-dose weekly erlotinib for CNS metastases from EGFR mutant non-small cell lung cancer. Neuro Oncol. 2011; 13(12):1364-9. PMC: 3223088. DOI: 10.1093/neuonc/nor121. View

Kapoor G, Gocke T, Chawla S, Whitmore R, Nabavizadeh A, Krejza J . Magnetic resonance perfusion-weighted imaging defines angiogenic subtypes of oligodendroglioma according to 1p19q and EGFR status. J Neurooncol. 2009; 92(3):373-86. DOI: 10.1007/s11060-009-9880-x. View

Jang S, Atkins M . Which drug, and when, for patients with BRAF-mutant melanoma?. Lancet Oncol. 2013; 14(2):e60-9. DOI: 10.1016/S1470-2045(12)70539-9. View

Jiang X, Asbach P, Willerding G, Dulce M, Xu K, Taupitz M . Dynamic contrast-enhanced MRI of ocular melanoma. Melanoma Res. 2015; 25(2):149-56. DOI: 10.1097/CMR.0000000000000142. View

Yokoi K, Kamiya N, Matsuguma H, Machida S, Hirose T, Mori K . Detection of brain metastasis in potentially operable non-small cell lung cancer: a comparison of CT and MRI. Chest. 1999; 115(3):714-9. DOI: 10.1378/chest.115.3.714. View

Kickingereder P, Sahm F, Wiestler B, Roethke M, Heiland S, Schlemmer H . Evaluation of microvascular permeability with dynamic contrast-enhanced MRI for the differentiation of primary CNS lymphoma and glioblastoma: radiologic-pathologic correlation. AJNR Am J Neuroradiol. 2014; 35(8):1503-8. PMC: 7964431. DOI: 10.3174/ajnr.A3915. View

Boxerman J, Schmainda K, Weisskoff R . Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol. 2006; 27(4):859-67. PMC: 8134002. View

10.

Jung B, Arevalo-Perez J, Lyo J, Holodny A, Karimi S, Young R . Comparison of Glioblastomas and Brain Metastases using Dynamic Contrast-Enhanced Perfusion MRI. J Neuroimaging. 2015; 26(2):240-6. PMC: 4753138. DOI: 10.1111/jon.12281. View

11.

Wood M, Vogel V, Ng A, Foxhall L, Goodwin P, Travis L . Second malignant neoplasms: assessment and strategies for risk reduction. J Clin Oncol. 2012; 30(30):3734-45. DOI: 10.1200/JCO.2012.41.8681. View

12.

Namasivayam S, Martin D, Saini S . Imaging of liver metastases: MRI. Cancer Imaging. 2007; 7:2-9. PMC: 1804118. DOI: 10.1102/1470-7330.2007.0002. View

13.

Al-Shamy G, Sawaya R . Management of brain metastases: the indispensable role of surgery. J Neurooncol. 2009; 92(3):275-82. DOI: 10.1007/s11060-009-9839-y. View

14.

Murase K . Efficient method for calculating kinetic parameters using T1-weighted dynamic contrast-enhanced magnetic resonance imaging. Magn Reson Med. 2004; 51(4):858-62. DOI: 10.1002/mrm.20022. View

15.

Hacklander T, Reichenbach J, Modder U . Comparison of cerebral blood volume measurements using the T1 and T2* methods in normal human brains and brain tumors. J Comput Assist Tomogr. 1997; 21(6):857-66. DOI: 10.1097/00004728-199711000-00003. View

16.

Kremer S, Grand S, Berger F, Hoffmann D, Pasquier B, Remy C . Dynamic contrast-enhanced MRI: differentiating melanoma and renal carcinoma metastases from high-grade astrocytomas and other metastases. Neuroradiology. 2003; 45(1):44-9. DOI: 10.1007/s00234-002-0886-8. View

17.

Owonikoko T, Arbiser J, Zelnak A, Shu H, Shim H, Robin A . Current approaches to the treatment of metastatic brain tumours. Nat Rev Clin Oncol. 2014; 11(4):203-22. PMC: 4041037. DOI: 10.1038/nrclinonc.2014.25. View

18.

Nieder C, Spanne O, Mehta M, Grosu A, Geinitz H . Presentation, patterns of care, and survival in patients with brain metastases: what has changed in the last 20 years?. Cancer. 2013; 117(11):2505-12. DOI: 10.1002/cncr.25707. View

19.

Ranjan T, Abrey L . Current management of metastatic brain disease. Neurotherapeutics. 2009; 6(3):598-603. PMC: 5084194. DOI: 10.1016/j.nurt.2009.04.012. View

20.

Travis L, Demark Wahnefried W, Allan J, Wood M, Ng A . Aetiology, genetics and prevention of secondary neoplasms in adult cancer survivors. Nat Rev Clin Oncol. 2013; 10(5):289-301. DOI: 10.1038/nrclinonc.2013.41. View